首页 > 最新文献

Journal of neuro-AIDS最新文献

英文 中文
Serial MRI in HIV Infection With and Without Neurologic Impairment. 伴或不伴神经损伤的HIV感染的序列MRI。
Pub Date : 1996-01-01 DOI: 10.1300/j128v01n04_05
G H Dooneief, J A Bello, G G Todak, M X Tang, K S Marder, Y Stern, R P Mayeux

To assess the relationship of longitudinal brain magnetic resonance imaging (MRI) and infection with human immunodeficiency virus (HIV), a cohort of HIV+ and HIV− gay men and injection drug users (IDU) were evaluated prospectively. Subjects underwent two evaluations including MRI scans, neurologic examinations, neuropsychological assessments and lymphocyte subset determinations one year apart. MRI changes over a one year period were analyzed with respect to serostatus, risk group, CD4 counts, neurological findings and neuropsychological performance. The frequency of MRI changes was no different in subjects with or without HIV infection and no new opportunistic infections or neoplasms were seen. However, among HIV+ subjects with CD4 count < 200 at the time of the initial scan, an increase in white matter hyperintensities was significantly more common. Also among HIV+ subjects, atrophy increased in association with declining CD4 count. Finally, subjects who developed significant neurologic deterioration in one year were much more likely to have increased atrophy. These results suggest that while there are morphological brain changes associated with HIV infection, they are most often seen in association with immunologic or neurologic deterioration.

为了评估纵向脑磁共振成像(MRI)与人类免疫缺陷病毒(HIV)感染的关系,一组HIV+和HIV−前瞻性评价男同性恋者和注射吸毒者(IDU)。受试者接受两次评估,包括MRI扫描、神经学检查、神经心理学评估和淋巴细胞亚群测定,间隔一年。分析了一年内的MRI变化,包括血清状态、危险组、CD4计数、神经学结果和神经心理学表现。有无HIV感染的受试者的MRI变化频率无差异,未见新的机会性感染或肿瘤。然而,在初始扫描时CD4计数< 200的HIV阳性受试者中,白质高信号的增加更为常见。同样,在HIV+受试者中,萎缩增加与CD4计数下降有关。最后,在一年内出现明显神经退化的受试者更有可能出现萎缩。这些结果表明,虽然存在与HIV感染相关的脑形态学改变,但它们通常与免疫或神经系统恶化有关。
{"title":"Serial MRI in HIV Infection With and Without Neurologic Impairment.","authors":"G H Dooneief,&nbsp;J A Bello,&nbsp;G G Todak,&nbsp;M X Tang,&nbsp;K S Marder,&nbsp;Y Stern,&nbsp;R P Mayeux","doi":"10.1300/j128v01n04_05","DOIUrl":"https://doi.org/10.1300/j128v01n04_05","url":null,"abstract":"<p><p>To assess the relationship of longitudinal brain magnetic resonance imaging (MRI) and infection with human immunodeficiency virus (HIV), a cohort of HIV+ and HIV&#8722; gay men and injection drug users (IDU) were evaluated prospectively. Subjects underwent two evaluations including MRI scans, neurologic examinations, neuropsychological assessments and lymphocyte subset determinations one year apart. MRI changes over a one year period were analyzed with respect to serostatus, risk group, CD4 counts, neurological findings and neuropsychological performance. The frequency of MRI changes was no different in subjects with or without HIV infection and no new opportunistic infections or neoplasms were seen. However, among HIV+ subjects with CD4 count < 200 at the time of the initial scan, an increase in white matter hyperintensities was significantly more common. Also among HIV+ subjects, atrophy increased in association with declining CD4 count. Finally, subjects who developed significant neurologic deterioration in one year were much more likely to have increased atrophy. These results suggest that while there are morphological brain changes associated with HIV infection, they are most often seen in association with immunologic or neurologic deterioration.</p>","PeriodicalId":73854,"journal":{"name":"Journal of neuro-AIDS","volume":"1 4","pages":"49-57"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26169475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pilot Study of Didanosine in Patients with HIV Dementia. 二腺苷在HIV痴呆患者中的初步研究。
Pub Date : 1996-01-01 DOI: 10.1300/j128v01n04_01
K D Kieburtz, R W Price, J J Sidtis, C Hall, M Grundman, C McLaren

In a pilot open-labeled study 10 subjects with AIDS dementia complex (ADC) were treated with didanosine. Only half of the subjects were able to complete the trial as a result of side effects. Five subjects exhibited improved performance on neuropsychological testing, but the mean change in performance in this small group was not statistically significant. The study suggests that this drug may have some value in ADC patients unable to tolerate other therapies, but that further study is needed to establish this firmly.

在一项试验性开放标签研究中,10名患有艾滋病痴呆复合物(ADC)的受试者接受了二腺苷治疗。由于副作用,只有一半的受试者能够完成试验。五名受试者在神经心理测试中表现出改善的表现,但这一小群人的平均表现变化没有统计学意义。该研究表明,该药物可能对不能耐受其他治疗的ADC患者有一定价值,但需要进一步的研究来证实这一点。
{"title":"Pilot Study of Didanosine in Patients with HIV Dementia.","authors":"K D Kieburtz,&nbsp;R W Price,&nbsp;J J Sidtis,&nbsp;C Hall,&nbsp;M Grundman,&nbsp;C McLaren","doi":"10.1300/j128v01n04_01","DOIUrl":"https://doi.org/10.1300/j128v01n04_01","url":null,"abstract":"<p><p>In a pilot open-labeled study 10 subjects with AIDS dementia complex (ADC) were treated with didanosine. Only half of the subjects were able to complete the trial as a result of side effects. Five subjects exhibited improved performance on neuropsychological testing, but the mean change in performance in this small group was not statistically significant. The study suggests that this drug may have some value in ADC patients unable to tolerate other therapies, but that further study is needed to establish this firmly.</p>","PeriodicalId":73854,"journal":{"name":"Journal of neuro-AIDS","volume":"1 4","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26170644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy. α干扰素在艾滋病相关进行性多灶性脑白质病中的作用。
Pub Date : 1996-01-01 DOI: 10.1300/j128v01n04_08
T Counihan, N Venna, D Craven, T D Sabin

Objective: To determine the efficacy of recombinant interferon alpha in the treatment of progressive multifocal leukoencephalopathy associated with the acquired immunodeficiency syndrome (AIDS).

Design: Open label, uncontrolled study.

Setting: Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.

Patients: Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.

Intervention: Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.

Results: None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.

Conclusions: Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.

目的:探讨重组干扰素α治疗获得性免疫缺陷综合征(AIDS)伴进行性多灶性白质脑病的疗效。设计:开放标签,非对照研究。地点:马萨诸塞州波士顿市医院神经内科和临床艾滋病项目。患者:连续4例经病理证实为进行性多灶性脑白质病的艾滋病患者。干预:每位患者接受α -干扰素治疗,持续4-12周,每日5-10万单位,皮下给药。此外,四人中有两人在同一时期口服阿昔洛韦2400毫克/天。结果:所有患者均无临床反应;平均生存期为14周。没有发现治疗的不良反应。结论:尽管有轶事证据表明α干扰素对非艾滋病患者进行性多灶性脑白质病变有效,但这些患者的经验表明,该药物对艾滋病相关PML没有益处。
{"title":"Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy.","authors":"T Counihan,&nbsp;N Venna,&nbsp;D Craven,&nbsp;T D Sabin","doi":"10.1300/j128v01n04_08","DOIUrl":"https://doi.org/10.1300/j128v01n04_08","url":null,"abstract":"<p><strong>Objective: </strong>To determine the efficacy of recombinant interferon alpha in the treatment of progressive multifocal leukoencephalopathy associated with the acquired immunodeficiency syndrome (AIDS).</p><p><strong>Design: </strong>Open label, uncontrolled study.</p><p><strong>Setting: </strong>Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.</p><p><strong>Patients: </strong>Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.</p><p><strong>Intervention: </strong>Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.</p><p><strong>Results: </strong>None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.</p><p><strong>Conclusions: </strong>Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.</p>","PeriodicalId":73854,"journal":{"name":"Journal of neuro-AIDS","volume":"1 4","pages":"79-88"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1300/j128v01n04_08","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26169478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
期刊
Journal of neuro-AIDS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1